Table 3.

TSH-receptor antibodies (TRAb) and thyroid dysfunction during Alemtuzumab treatment.

Patients and TRAb	(%)
Positive TRAb at baseline	0.0
De novo positive TRAb	38.0
Thyroid dysfunction and TRAb status
Positive TRAb	70.0
Hyperthyroidism and TRAb status
Positive TRAb	84.7
Graves’ disease and TRAb status
Positive TRAb	100
Hypothyroidism and TRAb status
Positive TRAb	76.7

Data elaborated from Daniels et al. (42).